| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6095123 | Gastroenterology | 2013 | 14 Pages |
Abstract
The combination of danoprevir, peginterferon alfa-2a, and ribavirin leads to high rates of SVR in patients with HCV genotype 1 infection, but high doses of danoprevir can lead to grade 4 increases in alanine aminotransferase. Studies of lower doses of danoprevir with ritonavir, to reduce overall danoprevir exposure while maintaining potent antiviral activity, are underway; Clinicaltrials.gov number, NCT00963885.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Patrick Marcellin, Curtis Cooper, Luis Balart, Dominique Larrey, Terry Box, Eric Yoshida, Eric Lawitz, Peter Buggisch, Peter Ferenci, Martin Weltman, Emily Labriola-Tompkins, Sophie Le Pogam, Isabel Nájera, Denise Thomas, Gregory Hooper,